Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Show more
Location: 11250 El Camino Real, San Diego, CA, 92130, United States | Website: https://skyebioscience.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
123.3M
52 Wk Range
$1.14 - $7.47
Previous Close
$3.94
Open
$3.87
Volume
398,927
Day Range
$3.87 - $4.17
Enterprise Value
70.7M
Cash
59.22M
Avg Qtr Burn
-7.429M
Insider Ownership
1.44%
Institutional Own.
80.79%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|